

EGFR ABfinity™ Recombinant Rabbit Monoclonal Antibody – Purified



Catalog no. 700994

(See product label for lot information)

Clone/PAD: 30H45L42
Isotype: IgG
Gene ID: 1956
Protein Acc. no.: P00533
Qty: 100 µg
Volume: 200 µl
Concentration: 0.5 mg/mL

Formulation

PBS + 0.09% sodium azide

Validation

Validated for use in ELISA

Immunogen

Recombinant protein

Sequence Identity

Human

Sequence Homology

Mouse

Expected Reactivity

Based on sequence identity and similarity, reactivity to human and Mouse is expected.

Storage

2-8°C for up to 1 month, -20°C for long term storage. Avoid repeated freezing and thawing.

Expiration Date

Expires one year from date of receipt when stored as instructed.

Background

Epidermal Growth Factor Receptor (EGFR) is a 175 kDa transmembrane glycoprotein which belongs to the tyrosine kinase superfamily (2, 4). EGFR acts as a receptor for epidermal growth factor (EGF) family (1, 2). Binding of EGFR to its ligands causes autophosphorylation of tyrosine kinase followed by activation of signal transduction of the pathways resulting in cell proliferation and differentiation (2). Deregulation of EGFR expression has been well established in several cancer including NSCLCs (3).

References

1. Bridges, A.J. (1999). The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. *Current medicinal chemistry* 6, 825-843.
2. Herbst, R.S. (2004). Review of epidermal growth factor receptor biology. *International journal of radiation oncology, biology, physics* 59, 21-26.
3. Khazaie, K., Schirmacher, V., and Lichtner, R.B. (1993). EGF receptor in neoplasia and metastasis. *Cancer metastasis reviews* 12, 255-274.
4. Raymond, E., Faivre, S., and Armand, J.P. (2000). Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. *Drugs* 60 Suppl 1, 15-23; discussion 41-12.
5. Zwick, E., Hackel, P.O., Prenzel, N., and Ullrich, A. (1999). The EGF receptor as central transducer of heterologous signalling systems. *Trends in pharmacological sciences* 20, 408-412.

Following applications had been tested during development. To make sure the consistency and reliability in the future lots, each lot is tested with antigen ELISA for specificity and potency. Each lot is also tested with SDS-PAGE, to ensure high purity.

Applications:

	Species	Test Material	Concentration
Sandwich ELISA	Human	A431 Cell Lysate	1-5 µg/ml

For Research Use Only. Not for human or animal therapeutic or diagnostic use.

www.invitrogen.com

Invitrogen Corporation • 7335 Executive Way • Frederick • MD 21704 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

For Research Use Only. Not for human or animal therapeutic or diagnostic use.

www.invitrogen.com

Invitrogen Corporation • 7335 Executive Way • Frederick • MD 21704 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com